Disease Domain | Count |
---|---|
Neoplasms | 2 |
Infectious Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
CAR-T | 2 |
Prophylactic vaccine | 1 |
Top 5 Target | Count |
---|---|
GPC3(Glypican-3) | 1 |
ALPP(alkaline phosphatase, placental) | 1 |
CENPF(centromere protein F) | 1 |
Target |
Mechanism CENPF modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD19 inhibitors [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GPC3 inhibitors [+2] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2024 |
Sponsor / Collaborator |
Start Date31 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GPC3-CART(Xinqiao Hospital of Chongqing) ( GPC3 ) | Hepatocellular Carcinoma More | Phase 2 Clinical |
Retroviral vector-transduced autologous T cells to express anti-ALPP CARs(Chongqing Xinqiao Hospital) ( ALPP ) | Ovarian Cancer More | Phase 2 |
Melioidosis Vaccine(Third Military Medical University) ( CENPF ) | Melioidosis More | Preclinical |
Anti-CD19 CAR-T cell therapy(Xuzhou Medical University) ( CD19 ) | Refractory Transformed Chronic Lymphocytic Leukemia More | Pending |